Joanne Langley, MD: The Need for Hepatitis B Preventive Care
The presenting IDWeek author discusses the implication of promising phase 3 data for a new HBV vaccine.
Karen Giuliano, PhD: Oral Care to Reduce Hospital Infections
New data may evidence oral care as a therapeutic measure to reduce bacterial and viral spread.
Brigham and Women's Provides Blueprint for Hospital COVID-19 Protection
The hospital found just 2 cases in their first 12 weeks were borne in the facility. A study author provides insight.
Improving on an Infectious Disease Referral Program for Addiction Care
A cross-specialty collaboration to mitigate inpatient cases of opioid use disorder has had early success; developers want to grow it.
How Does IV Immunoglobulin Work for COVID-19?
An investigator shares detail into how the neutralizing, immune-signaling molecule may provide continued success against the virus.
COVID-19 Case Studies: How Far Science Has Come
Ravina Kullar, PharmD, MPH, reflects on rapid advances in COVID-19 treatment understanding during IDWeek 2020.
Hospital Antibiotic Prescribing Linked to MRSA Prevalence
New data suggest collaboration between hospital prescribers and stewardship teams is still not perfected.
Antibiotic Prescribing Increased in VA Clinics During COVID-19 Spread
New data show the pandemic, and a lack of efficacious therapies, did harm to 4 years' worth of stewardship.
Looking at INSTI Therapy and Metabolic Adverse Events
Investigators wanted to examine spontaneously reported adverse events and whether they were cause for concern.
FDA Clears AstraZeneca COVID-19 Vaccine to Resume US Trial
The conclusion to the independent safety review punctuates a 50-day period of scrutiny and discussion around 2 non-fatal adverse events reported in patients.
Delving Deeper into Post Ebola Syndrome
Here is a look at the patterns within the variety of symptoms and presentations during physician exams.
Understanding Cefiderocol and the Results of the CREDIBLE-CR Study
A presenting author offers greater study insights into this novel therapy for the treatment of serious infections.
Rates of Invasive Pulmonary Aspergillosis in ICU Patients With Influenza Far Lower Than Previously Thought
The study population comprised 224 patients admitted to the ICU with influenza, and the overall rate of IPA was 3.1% (7/224).
Moderna Reaches Full Enrollment for its COVID-19 Vaccine
Its phase 3 COVE trial enrollment is complete and the company is working towards its goal of FDA approval.
Long-Term Care Facility Residence Associated With Atypical Presentation of COVID-19
Reports of hospitalized older adults with COVID-19 who do not experience the classic symptoms are on the rise.
Fosmanogepix Shows Promise as an Effective Novel Antifungal in POC Trial
“The compound appears to be safe and well-tolerated, [and we observed] excellent efficacy based on a very small sample size,” Peter G. Pappas, MD, said.
Antibiotic Stewardship in the Urgent Care Setting Cuts Antibiotic Prescribing for Respiratory Encounters
The urgent care setting is a prime target for antimicrobial stewardship efforts as it becomes an increasingly prevalent form of healthcare delivery.
Starting Addiction Care with Injection Drug-Infected Patients
A firsthand look into a Kentucky program that's initiated opioid use disorder care in recurring HIV, hepatitis C patients.
Remdesivir Becomes First Fully FDA-Approved COVID-19 Treatment in US
The full approval is based on 3 randomized controlled trials showing benefit of remdesivir compared with placebo across multiple outcome assessments.
Pediatric Antibiotic Prescribing Remains High in ED, Despite Testing
New data highlight the need for more antimicrobial stewardship adoption in emergency care settings.
Multidrug-Resistant Infection is Diverse, Frequent in Hospital Setting
Tebipenem Pivoxil Hydrobromide is Non-inferior to IV Ertapenem
Results from the Pivotal ADAPT-PO study were reported.
FURI Study Reports on Ibrexafungerp for Treatment of Refractory Fungal Diseases
Results show medication provides therapeutic response for Candida.
20-Valent Pneumococcal Conjugate Vaccine Comparable to Prevnar 13 in Phase 3 Study
In an effort to expand serotype coverage beyond 13, a 20-valent pneumococcal conjugate vaccine, PCV20, is currently in development.
POLAR Study: Switch to Long-Acting Cabotegravir-Rilpivirine Every 2 Months Is Safe, Tolerable
Overall, 88% of participants who received long-acting therapy preferred CAB LA+RPV LA compared with oral treatment.
BRAAVE 2020: Biktarvy Noninferior as a Switch Treatment for Black Americans Living With HIV
The results support B/F/TAF as a switch option for Black Americans who are virologically suppressed, including individuals with a history of treatment failure or pre-existing resistance.
COVID-19’s Effect on Clinical Trials of Long-Acting Cabotegravir and Rilpivirine for HIV Infection
How has the COVID-19 pandemic affected clinical trial site restrictions, drug delivery, dosing, patient monitoring, and follow-up?
SARS-CoV-2 Household Transmission Risk is Significantly High
New data presented at IDWeek showed more than half observed households with a COVID-19 case reported a secondary infection, oftentimes within 3 days.
Intravenous Immunoglobulin Beneficial for Severe COVID-19
Phase 1 data and a history of benefit for worsening respiratory infections show promise for the therapy.
Tri-Antigenic Hepatitis B Vaccine Elicits Significant Immunity
New head-to-head phase 3 data show a promising potential new HBV vaccine may join the market in the near future.
